Marker Therapeutics Partners With Cellipont For MT-601 Manufacturing To Accelerate Clinical And Commercial Plans

Marker Therapeutics has entered into a collaboration with Cellipont Bioservices to support the cGMP manufacturing of its lead T cell therapy, MT-601. MT-601 is part of Marker’s Multi-Antigen Recognizing (MAR)-T cell platform and is currently under evaluation in the Phase 1 APOLLO study for patients with lymphoma who have either relapsed after, or are ineligible for, anti-CD19 CAR-T therapy. This collaboration marks a key step in scaling the clinical supply chain as the therapy progresses toward late-stage development.

“This exciting collaboration with Cellipont is a critical step forward as we prepare for a potential pivotal trial of MT-601 in patients with diffuse large B-cell lymphoma (DLBCL) who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy. The promising clinical data we have observed in the ongoing APOLLO study reinforce our commitment to advancing MT-601 to address an important area of unmet need. We sought a manufacturing partner with the capabilities to support not only mid-to-late-stage clinical development but also future commercial production, and we believe Cellipont is well-positioned to support us as we advance our program through the next stages,” commented Dr. Juan Vera, President and CEO of Marker Therapeutics. 

The APOLLO study has shown encouraging early data, with a favorable safety profile and clinical responses in 7 out of 9 patients (78%) treated with MT-601, including complete responses in 4 patients (44.4%) observed within four weeks of treatment. These results underscore the potential of Marker’s MAR-T platform in treating hard-to-treat hematological malignancies.

Darren Head, CEO of Cellipont Bioservices, commented, “We are proud to support Marker Therapeutics in advancing MT-601, a compelling MAR-T cell therapy that is anticipated to address a major need in the cell therapy space. Our team is dedicated to enabling the success of next-generation immunotherapies, and Marker’s platform exemplifies the innovation and translational potential that defines the future of cancer treatment. This partnership reflects our shared focus on quality, agility, and impact for patients.”

Under the new agreement, Cellipont will provide technology transfer and manufacturing support, leveraging its advanced cell therapy production facility in The Woodlands, Texas. The 76,000-square-foot site features modular cleanrooms and integrated quality control labs, enabling flexible, scalable, and compliant manufacturing. This partnership is expected to streamline MT-601’s clinical progression and support future pivotal trials and commercial readiness.